Inclusion Criteria:

• Patients must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up
• Histologically or cytologically confirmed diagnosis of advanced solid tumor that has failed standard therapy or for which there is no standard therapy. Patients should have unresectable or metastatic disease.
• Age =18 years.
• Adequate organ system function as defined by the protocol.
• ECOG performance value of 0 or 1.
• Measurable disease or evaluable disease on CT scan.
• Prior radiotherapy and chemotherapy is permissible, provided at least 4 weeks have elapsed since the last treatment and have recovered from any related toxicities.
• Metastatic disease to the brain should have definitive therapy for the metastatic disease and be asymptomatic.
• Have an LVEF greater than or equal to 50%.
• Women of childbearing potential must have a negative pregnancy test within 2 weeks of starting study drug and use acceptable birth control methods as outlined in the protocol.
• Women may participate if they are of non childbearing potential (bilateral tubal ligation, hysterectomy, post menopausal or bilateral ovariectomy.
• Males with female partners of childbearing potential may participate if they practice acceptable methods of birth control as outlined in the study protocol.
• Able to swallow and retain oral medications.
• Less than or equal to 2 prior lines of chemotherapy for advanced disease.
• Life expectancy of at least 12 weeks.

Exclusion Criteria:

• Prior use of pazopanib or prior treatment with epirubicin greater than 450 mg/mm2 or doxorubicin greater than 240 mg/mm2 cumulative dose. Prior therapy with other angiogenesis inhibitors is permitted.
• Clinically significant gastrointestinal abnormalities which might interfere with oral dosing.
• Uncontrolled infection.
• QTc > 480 msecs.

• One of more of the following within the past 6 months:

  • Cardiac angioplasty or stenting
  • Myocardial infarction
  • Unstable angina
  • Symptomatic peripheral vascular disease
  • Class III or IV congestive heart failure
• Any major surgery or trauma within the last 28 days and or presence of non-healing wound, fracture, or ulcer.
• Any unstable or serious concurrent condition.
• Poorly controlled hypertension [defined as systolic blood pressure (SBP) of =140mmHg or diastolic blood pressure (DBP) of = 90mmHg].
• History of cerebrovascular accident (CVA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Subjects with a recent DVT who have been treated with therapeutic agents (excluding therapeutic warfarin) for at least 6 weeks are eligible.
• Hemoptysis within 6 weeks prior to first dose of study drug.
• Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with patient's safety, provision of informed consent, or compliance to study procedures.
• Is unable or unwilling to discontinue prohibited medications for 14 days or five half-lives of a drug prior to Visit 1 and for the duration of the study.
• Use of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug.
• Is now undergoing and/or has undergone within 28 days immediately prior to first dose of study drug, any cancer therapy (major surgery, investigational agent, tumor embolization, chemotherapy, radiation therapy, immunotherapy, biological therapy, or hormonal therapy).
• Active bleeding or bleeding diathesis.
• Clinically assessed as having inadequate venous access for PK sampling.
• Lactating and pregnant women should discontinue lactation prior to first use of study drug and refrain from nursing throughout the treatment period and for 14 days after final dose.